|
|
News Breaks
|
November 9, 2009
|
| 07:15 EDT |  | CGEN |
| theflyonthewall.com: | Compugen discovers genetic biomarker for Predisposition to Type 2 diabetes | | Compugen announced the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes. This new biomarker was discovered using Compugen’s GeneVa® platform, which consists of an in silico database of approximately 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides. :theflyonthewall.com |
|
|
News For CGEN From The Last 14 Days Check below for free stories on CGEN the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 7, 2012
|
| 07:10 EDT |  | CGEN |
| | 07:08 EDT | | CGEN |
|
|
February 2, 2012
|
| 06:14 EDT | | CGEN |
|
|
January 30, 2012
|
| 07:00 EDT | | CGEN |
| theflyonthewall.com: | Compugen presents three product candidates for treatment of autoimmune diseases | | Speaking today at the 4th Immunotherapeutics & Immunomonitoring Conference in San Diego, Dr. Galit Rotman, Chief Scientist of Therapeutics at Compugen, presented data demonstrating the therapeutic efficacy of CGEN-15001, CGEN-15021 and CGEN-15091 in animal models of multiple sclerosis and the therapeutic efficacy of CGEN-15001 and CGEN-15021 in animal models of rheumatoid arthritis. CGEN-15001, CGEN-15021 and CGEN-15091 are predicted B7/CD28-like proteins discovered using Compugen’s Protein Family Members Discovery Platform. :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information